Nirogacestat in Ovarian Granulosa Cell Tumors
Public ClinicalTrials.gov record NCT05348356. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2 Trial of Nirogacestat in Patients With Recurrent Ovarian Granulosa Cell Tumors
Study identification
- NCT ID
- NCT05348356
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- SpringWorks Therapeutics, Inc.
- Industry
- Enrollment
- 53 participants
Conditions and interventions
Interventions
- Nirogacestat Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 29, 2022
- Primary completion
- Jul 7, 2025
- Completion
- Jul 13, 2025
- Last update posted
- Dec 14, 2025
2022 – 2025
United States locations
- U.S. sites
- 16
- U.S. states
- 12
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| USC/Norris Comprehensive Cancer Center | Los Angeles | California | 90033 | — |
| UCLA-JCCC Dept. of OBGYN - Women's Health Clinical Research Unit | Los Angeles | California | 90095 | — |
| AdventHealth Orlando | Orlando | Florida | 32804 | — |
| Orlando Health Cancer Institute | Orlando | Florida | 32806 | — |
| H. Lee Moffitt Cancer Center and Research Institute | Tampa | Florida | 33612 | — |
| Women's Cancer Care | Covington | Louisiana | 70433 | — |
| Greater Baltimore Medical Center | Baltimore | Maryland | 21204 | — |
| Dana-Farber Cancer Institute | Boston | Massachusetts | 02215 | — |
| David C. Pratt Cancer Center | St Louis | Missouri | 63141 | — |
| University of New Mexico Comprehensive Cancer Center | Albuquerque | New Mexico | 87102 | — |
| Columbia University Medical Center | New York | New York | 10032 | — |
| Memorial Sloan Kettering Cancer Institute | New York | New York | 10065 | — |
| Women's Cancer Center at Kettering | Kettering | Ohio | 45429 | — |
| OU Health Stephenson Cancer Center | Oklahoma City | Oklahoma | 73104 | — |
| UW/Fred Hutch Cancer Center | Seattle | Washington | 98109 | — |
| Froedtert and Medical College of Wisconsin | Milwaukee | Wisconsin | 53226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 5 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05348356, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 14, 2025 · Synced May 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05348356 live on ClinicalTrials.gov.